In the JournalsPerspective

Algorithm predicts diabetic retinopathy progression

September 27, 2019
A deep learning algorithm developed by Genentech and Roche researchers predicts a patient’s diabetic retinopathy progression using color fundus…

Phase 3b trial to evaluate brolucizumab for wet AMD

September 26, 2019
Novartis announced a phase 3b clinical trial to evaluate brolucizumab vs. aflibercept in the treatment of wet age-related macular degeneration. The…

Meeting News

Topcon launches Maestro2 OCT

September 25, 2019
LAS VEGAS – Topcon announced the launch of the Maestro2 Automated OCT/Fundus Camera with OCT angiography here at Vision Expo West. Building on…

FDA fast tracks potential treatment to prevent proliferative vitreoretinopathy

September 25, 2019
The FDA has granted fast track designation to ADX-2191 for the prevention of proliferative vitreoretinopathy, Aldeyra Therapeutics announced in a…

In the JournalsPerspective

OCT-GCC more sensitive at detecting chiasmal compression

September 23, 2019
The use of OCT-ganglion cell complex analysis may be a more effective way to detect compressive chiasmopathy or optic neuropathy early on, according…

In the JournalsPerspective

OCT may indicate neurological changes in patients with frequent head trauma

September 23, 2019
The use of OCT could determine retinal biomarkers of neuropathological change after neurological trauma, according to findings published in Eye and

Feature

Q&A: My Home in Sight empowers people living with wet AMD

September 23, 2019
To better help patients with wet age-related macular degeneration continue to live independently, Novartis recently partnered with celebrity interior…

Meeting NewsVideo

VIDEO: Diabetes, hypertension often diagnosed in eye exam

September 19, 2019
LAS VEGAS – Diabetes and hypertension are two of the most common systemic diseases that optometrists may uncover during an eye exam, Jeff

Meeting News

Benefits of myopia control outweigh risks

September 19, 2019
LAS VEGAS – Slowing the progression of myopia can reduce the risk of other ocular pathology, with these benefits outweighing the risks of…

Ocugen gene therapy receives orphan drug designation

September 18, 2019
OCU400, a gene therapy candidate, has received a second orphan drug designation from the FDA for the treatment of CEP290 mutation associated retinal…

Xephilio OCT-A1 receives 510(k) clearance

September 17, 2019
The FDA has granted 510(k) clearance to Canon U.S.A.’s Xephilio OCT-A1 OCT device, according to a press release. Together with the RX Capture…

Augmented reality visual aids may improve mobility in RP patients

September 13, 2019
Use of augmented reality low-vision aids for patients with retinitis pigmentosa may assist with mobility and grasp, a recent study suggests. …

Better anatomical improvements seen with OPT-302 with ranibizumab vs. ranibizumab alone

September 13, 2019
Patients treated with OPT-302 from Opthea Limited plus ranibizumab demonstrated better anatomical changes over those treated with ranibizumab alone…

No anti-VEGF rescue injections needed in OPTIC phase 1 trial of ADVM-022

September 12, 2019
An intravitreal dose of ADVM-022, a gene therapy designed for long-term VEGF suppression via the expression of aflibercept, resulted in no anti-VEGF…

Alimera expands Iluvien distribution agreement with Horus

September 12, 2019
Alimera Sciences and Horus Pharma have expanded a distribution agreement to allow Horus to introduce Iluvien for diabetic macular edema and…

In the Journals

Visual, anatomic gains maintained with Eylea monotherapy for PCV

September 11, 2019
Visual and anatomical gains made with aflibercept monotherapy for polypoidal choroidal vasculopathy were maintained long term, according to a study…

Meeting News

Euretina allocates funds to research management of submacular hemorrhage in wet AMD

September 10, 2019
PARIS — Partnering with Fight for Sight, the European Society of Retina Specialists will award a 2 million euros grant to a research project…

Wize Pharma licenses Copernicus’ gene therapy technology

September 10, 2019
Wize Pharma has entered into an exclusive license agreement to develop and commercialize products based on non-viral gene therapy technology from…

Oxurion’s plasma kallikrein inhibitor shows positive phase 1 study results

September 9, 2019
Phase 1 study results for THR-149, Oxurion’s plasma kallikrein inhibitor, showed it to be safe and well tolerated with a rapid onset of action…

FDA, European Medicines Agency advance abicipar pegol applications for wet AMD

September 9, 2019
The FDA has accepted a biologics license application and the European Medicines Agency has validated a marketing authorization application for…